<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05104437</url>
  </required_header>
  <id_info>
    <org_study_id>COVAX BOOSTER (HT/DM)-Wuhan</org_study_id>
    <nct_id>NCT05104437</nct_id>
  </id_info>
  <brief_title>Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes</brief_title>
  <official_title>A Post-marketing Clinical Study of a Third Dose of the Inactivated SARS-CoV-2 Vaccine (Vero Cells) (Produced in Wuhan): Immunogenicity, Safety and Antibody Persistence Assessments in Patients With Hypertension and/or Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Biotec Group Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guizhou Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Institute of Biological Products Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>China National Biotec Group Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the post-marketing immunogenicity, safety and antibody persistence of the third&#xD;
      dose (booster) of Covid-19 vaccine in patients aged 60 years or older with hypertension&#xD;
      and/or diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After giving informed consent, patients with hypertension, patients with diabetes, patients&#xD;
      with both diseases, and healthy controls, all aged 60 years or older, are given a third doses&#xD;
      of the inactivated SARS-CoV-2 vaccine (Vero cells).&#xD;
&#xD;
      These subjects are all from the &quot;COVAX (HT/DM)-Wuhan&quot; clinical trial (NCT05065892). 50% of&#xD;
      them receive the booster vaccine 3 months after the second dose (0-1-4 schedule); 50% of them&#xD;
      receive the booster vaccine 5 months after the second dose (0-1-6 schedule).&#xD;
&#xD;
      Venous blood samples are collected before the booster dose and on day 28 after the booster&#xD;
      dose to evaluate the immunogenicity of the vaccine.&#xD;
&#xD;
      Venous blood samples are also collected on day 84/168/252/336 after the booster dose to&#xD;
      evaluate the antibody persistence of the vaccine.&#xD;
&#xD;
      Adverse events are actively recorded on a diary card once daily from day 0 to day 7 and once&#xD;
      from day 8 to day 21 after the booster dose. Serious adverse events (SAE) are collected&#xD;
      within 6 months after the booster dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Serum testing technicians will be masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion rate</measure>
    <time_frame>Up to 28 days after the booster dose</time_frame>
    <description>the rate of positive seroconversion against coronavirus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutralizing antibody level</measure>
    <time_frame>Up to 28 days after the booster dose</time_frame>
    <description>neutralizing antibody level against coronavirus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutralizing antibody level</measure>
    <time_frame>Up to 84 days after the booster dose</time_frame>
    <description>neutralizing antibody level against coronavirus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutralizing antibody level</measure>
    <time_frame>Up to 168 days after the booster dose</time_frame>
    <description>neutralizing antibody level against coronavirus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutralizing antibody level</measure>
    <time_frame>Up to 252 days after the booster dose</time_frame>
    <description>neutralizing antibody level against coronavirus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutralizing antibody level</measure>
    <time_frame>Up to 336 days after the booster dose</time_frame>
    <description>neutralizing antibody level against coronavirus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events following vaccination</measure>
    <time_frame>Up to 6 months after the booster dose</time_frame>
    <description>analyse the incidence of adverse events following immunization, both solicited and unsolicited</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1440</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>0-1-4 schedule group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive the booster vaccine 3 months after the second dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0-1-6 schedule group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive the booster vaccine 5 months after the second dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Covid-19 vaccine (0-1-4 schedule)</intervention_name>
    <description>Subjects receive the booster vaccine 3 months after the second dose.</description>
    <arm_group_label>0-1-4 schedule group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Covid-19 vaccine (0-1-6 schedule)</intervention_name>
    <description>Subjects receive the booster vaccine 5 months after the second dose.</description>
    <arm_group_label>0-1-6 schedule group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participate in the clinical trial &quot;NCT05065892&quot;.&#xD;
&#xD;
          -  ≥60 years old individuals with full civil capacity.&#xD;
&#xD;
          -  Clinically confirmed body temperature of &lt;37.3°C before enrolling in this study.&#xD;
&#xD;
          -  Able and willing to participate in the study plan during the entire study and&#xD;
             follow-up period.&#xD;
&#xD;
          -  Capable of understanding the study procedures, willing to sign the informed consent&#xD;
             form, and able to comply with the requirements of the clinical study protocol.&#xD;
&#xD;
          -  Inclusion criteria for patients with hypertension and/or diabetes: Hypertension and/or&#xD;
             diabetes definitively diagnosed by a community-level or higher medical institution.&#xD;
             Patients with hypertension: systolic pressure &lt;160 mmHg and diastolic pressure &lt;100&#xD;
             mmHg on the day of immunization achieved by lifestyle adjustment and/or drug&#xD;
             treatment; patients with diabetes: fasting glucose ≤13.9 mmol/L on the day of (or&#xD;
             within 3 days before) immunization achieved by lifestyle adjustment and/or drug&#xD;
             treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously confirmed or asymptomatic COVID-19 patient.&#xD;
&#xD;
          -  Has been immunized with a SARS-CoV-2 vaccine.&#xD;
&#xD;
          -  Illiterate.&#xD;
&#xD;
          -  Known allergy to any ingredient (including excipient) of this product.&#xD;
&#xD;
          -  Received non-specific immunoglobulin injection within 1 month before enrollment.&#xD;
&#xD;
          -  Received a live attenuated vaccine within 1 month before immunization or other vaccine&#xD;
             within 14 days before immunization.&#xD;
&#xD;
          -  Previous serious allergy to vaccine (e.g., acute allergic reaction, urticaria,&#xD;
             angioedema, and dyspnea).&#xD;
&#xD;
          -  Has uncontrolled epilepsy and other progressive neurological disorders; history of&#xD;
             Guillain-Barré syndrome.&#xD;
&#xD;
          -  Severe respiratory disorders, severe hepatic and renal diseases, malignancies, and&#xD;
             various acute diseases or acute onset of chronic diseases.&#xD;
&#xD;
          -  Diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma,&#xD;
             leukemia, or other autoimmune diseases.&#xD;
&#xD;
          -  Definitively diagnosed with thrombocytopenia or history of other coagulation disorders&#xD;
             that may cause subcutaneous injection to be contraindicated.&#xD;
&#xD;
          -  Currently experiencing acute complications (ketoacidosis, hyperosmolar state, lactic&#xD;
             acidosis, etc.) of diabetes; or within 2 weeks after recovery from these&#xD;
             complications.&#xD;
&#xD;
          -  Other physical conditions judged by the investigator that render the patient&#xD;
             unsuitable for participation in the clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ruizhi ZHANG</last_name>
    <phone>+86-13985441115</phone>
    <email>919987774@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nan'an Center for Disease Control and Prevention</name>
      <address>
        <city>Quanzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Songtao Miao Autonomous County Center for Disease Control and Prevention</name>
      <address>
        <city>Tongren</city>
        <state>Guizhou</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>You County Center for Disease Control and Prevention</name>
      <address>
        <city>Zhuzhou</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 30, 2021</study_first_submitted>
  <study_first_submitted_qc>October 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>October 30, 2021</last_update_submitted>
  <last_update_submitted_qc>October 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

